 Aerpio Pharmaceuticals, Inc. Aerpio ARPO, a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader KOL call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time. The call will feature presentations by Dr. Paul Kaufman M.D. University of Wisconsin and Dr. Janey Wiggs, M.D., Ph.D. Massachusetts Eye and Ear Infirmary and Harvard Medical School, who will discuss the current glaucoma treatment landscape and unmet medical needs, as well as the role of the Tie2 receptor in maintaining intraocular pressure. 